7 articles tagged with #pharmaceuticals. AI-curated summaries with sentiment analysis and key takeaways from 50+ sources.
The US has initiated a tariff investigation into Germany regarding pharmaceuticals, escalating existing US-EU trade tensions. The investigation risks deepening trade rifts between the two economies and could disrupt pharmaceutical markets while triggering retaliatory measures from the EU.
The US has initiated a Section 301 investigation into Germany's pharmaceutical pricing policies, a trade action that could escalate transatlantic tensions and establish precedent for future disputes over drug pricing regulations globally.
The Trump administration has implemented 100% tariffs on imported pharmaceuticals, creating significant uncertainty around potential EU retaliation. This trade action threatens to disrupt global pharmaceutical supply chains and strain US-EU relations, with broader implications for international commerce and economic stability.
An article examining a major doping scandal in Olympic sports involving dozens of athletes using various performance-enhancing drugs and hormones. The piece uses this incident as a lens to explore broader cultural attitudes toward competition, winning, and pharmaceutical enhancement.
A comprehensive evaluation of Boltz-2, an AI-based drug discovery tool, reveals significant limitations in predicting protein-ligand binding structures and affinities. The study found only weak correlations with physics-based methods and concluded that while useful for initial screening, Boltz-2 lacks the precision required for reliable drug lead identification.
Researchers developed a pharmacology knowledge graph for drug repurposing and found that removing chemical structure representations improved performance while dramatically reducing computational requirements. The study showed that drug behavior can be accurately predicted using only target protein information and network topology, with larger datasets proving more valuable than complex models.
UPS is investing nearly $50 million in temperature-controlled logistics facilities to capitalize on surging demand for GLP-1 drug deliveries. Major freight companies are repositioning themselves as healthcare logistics providers, viewing the sector as a recession-resistant business opportunity amid booming pharmaceutical demand.
